Education
About Us
Working with TipRanks
Follow Us
Dexcom (GB:0A4M)
LSE:0A4M
0A4M Stock Chart & Stats
$56.00
$0.07(0.08%)
At close: 4:00 PM EST
$56.00
$0.07(0.08%)
Day’s Range― - ―
52-Week Range$56.00 - $90.77
Previous CloseN/A
Volume1.55K
Average Volume (3M)125.00
Market Cap
$21.45B
Enterprise Value$26.67B
Total Cash (Recent Filing)$3.32B
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)31.2
Beta0.26
Next Earnings
Feb 05, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding390,016,270
10 Day Avg. Volume298
30 Day Avg. Volume125
Financial Highlights & Ratios
PEG Ratio39.32
Price to Book (P/B)14.97
Price to Sales (P/S)7.80
P/FCF Ratio49.89
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit10.01
Enterprise Value/Ebitda21.90
Forecast
1Y Price Target
$88.05Price Target Upside57.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDexcom reported Q3 revenue of $1.209B, a $30M beat on consensus estimates.
Product Quality ImprovementsManagement cited favorable trends in many metrics, including sensor performance, wear time, complaint rates, and warranty replacements.
Share Repurchase PlansManagement has plans to repurchase shares, indicating confidence in the company’s future.
Bears Say
Guidance ConcernsThe guide was disappointing with 2025 revenue lifted to reflect Q3 results but GM and adjusted EBITDA guidance lowered as costs related to quality issues continue to impact the P&L.
Investor SentimentInvestor sentiment on Dexcom has been negative over the past several months due to concerns about high Street estimates for 2026 and noise around accuracy issues impacting new patient starts.
Reputational RisksReputational damage needs to be avoided as Dexcom could become exposed once ABT's Libre 3 Plus gains broader AID integration.
Dexcom News
0A4M FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest share price was $56.00 and its highest was $90.77 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $21.45B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 05, 2026 which is in 88 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 30, 2025. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.576 by $0.034.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.65.
How many shares outstanding does Dexcom have?
Dexcom has 390,016,270 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.61 in its last earnings report, beating expectations of $0.576. Following the earnings report the stock price went down -16.765%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in GB:0A4M
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.05 (57.23% Upside)
$88.05 (57.23% Upside)
Blogger Sentiment
Bullish
GB:0A4M Sentiment 75%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $15.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.18%
12-Months-Change
Fundamentals
Return on Equity
30.63%
Trailing 12-Months
Asset Growth
18.04%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
0A4M Company Deck
0A4M Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
DexCom's earnings call highlighted robust revenue growth and strategic product expansions, particularly in type 2 diabetes CGM coverage, and noted the introduction of innovative products like DexCom Smart Basal. However, challenges in gross margin management and quality issues with the G7 sensor deployment were noted. The sentiment is buoyed by positive financial performance and strategic advancements, despite some operational challenges.View all GB:0A4M earnings summaries0A4M Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
0A4M Stock 12 Month Forecast
Average Price Target
$88.05
▲(57.23% Upside)
Technical Analysis
Edwards Lifesciences
―
Insulet
―
Smith & Nephew Snats
―
Steris
―
Tandem Diabetes Care
―
Options Prices
Currently, No data available
---